Inaktiver Wert

Alexza Pharmaceuticals, Inc. Aktie Nasdaq

Aktien

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

Alexza Pharmaceuticals : Reports Fourth Quarter and Year End 2015 Financial Results	28.03.16
Alexza Pharmaceuticals : to Report 2015 Year End Financial Results and Provide Company Update on Monday, March 28, 2016	15.03.16
Alexza Pharmaceuticals : Receives Positive Nasdaq Listing Determination	09.03.16
Alexza Pharmaceuticals : Confirms Grupo Ferrer Non-binding Letter of Intent	27.02.16
Alexza Pharmaceuticals : Reacquires U.S. Commercial Rights for ADASUVE® (loxapine) inhalation powder	24.02.16

Manager	Titel	Alter	Seit
Stacy Palermini DFI	Director of Finance/CFO	-	01.01.03
Tatjana Naranda PSD	President	-	01.01.05
Wolfgang Schmidt PRN	Corporate Officer/Principal	-	01.05.19

Aufsichtsräte	Titel	Alter	Seit
Jorge Ramentol Massana BRD	Director/Board Member	-	21.06.16
Joan Fanés Trillo BRD	Director/Board Member	-	21.06.16
Sergio Ferrer-Salat Serra di Migni BRD	Director/Board Member	-	21.06.16

Sektor

	% 1. Jan.	Kap.
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122 Mrd.
REGENERON PHARMACEUTICALS, INC.	+17.75%	112 Mrd.
ARGENX SE	+17.23%	25.91 Mrd.
BIONTECH SE	-24.11%	19.33 Mrd.
GENMAB A/S	-18.56%	16.17 Mrd.
BEIGENE, LTD.	-18.47%	15.6 Mrd.
WUXI APPTEC CO., LTD.	-47.75%	14.65 Mrd.
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34 Mrd.
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14 Mrd.